Inclusion Criteria:

          1. Histologically-proven, ER-positive, HER2-negative locally advanced, inoperable, and/or
             metastatic breast cancer.

          2. Female patients with menopausal status:

             i. Postmenopausal status defined as meeting at least one of the following criteria:

               1. Have undergone a bilateral oophorectomy any time in life;

               2. Age ≥60 years, or

               3. Age <60 years but have cessation of regular menses ≥12 months with follicle
                  stimulating hormone (FSH) value >40 milli-international units per milliliter
                  (mIU/mL) and an estradiol value <40 picograms per milliliter (pg/mL) (140
                  picomoles per liter [pmol/L]).

             ii. Premenopausal or perimenopausal concurrently given a luteinizing hormone-releasing
             hormone (LHRH) agonist starting at least 4 weeks before the start of trial therapy and
             is planned to continue LHRH agonist during the study.

          3. Patients meeting all the following criteria:

               1. Has had at least 6 months of endocrine therapy for metastatic ER+ breast cancer
                  prior to disease progression;

               2. Limited number of prior chemotherapy, endocrine therapy, and targeted therapy for
                  advanced or metastatic disease

               3. Radiological or objective evidence of disease progression on or after the last
                  systemic therapy prior to starting current study treatment.

               4. For phase Ia: Not eligible for standard therapy that would confer clinical
                  benefit to the patient.

        Exclusion Criteria:

          1. Patients with prior anticancer or investigational drug treatment within the following
             windows are excluded:

          2. Participants with prior anticancer or investigational drug treatment within the
             following windows are excluded:

               1. Any anti-cancer therapy (including endocrine therapy, chemotherapy, targeted
                  therapy, etc.) less than 30 days before first dose of study treatment.

               2. Any investigational drug therapy less than 28 days or 4 half-lives (whichever is
                  shorter) prior to first dose of study treatment.

          3. Patients with untreated or symptomatic or progressive central nervous system (CNS)
             metastases.

               -  Other protocol defined inclusion/exclusion criteria could apply